Evidence map›Paper›PMID 32706839›Full record

ArticlePLoS pathogens2020

Comparative transcriptome analysis of endemic and epidemic Kaposi's sarcoma (KS) lesions and the secondary role of HIV-1 in KS pathogenesis.

Salum J Lidenge, Andrew V Kossenkov, For Yue Tso, Jayamanna Wickramasinghe, Sara R Privatt, Owen Ngalamika, John R Ngowi, Julius Mwaiselage, Paul M Lieberman, John T West and 1 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in PLoS pathogens, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Spatial Profiling Shows That Lymphatic Endothelial Cells Form the Core of Kaposi Sarcoma (KS).Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Salum J LidengeNebraska Center for Virology and the School of Biological Sciences, University of Nebraska, Lincoln, Nebraska, United States of America.
Andrew V KossenkovWistar Institute, Philadelphia, Pennsylvania, United States of America.
For Yue TsoNebraska Center for Virology and the School of Biological Sciences, University of Nebraska, Lincoln, Nebraska, United States of America.
Jayamanna WickramasingheWistar Institute, Philadelphia, Pennsylvania, United States of America.
Sara R PrivattNebraska Center for Virology and the School of Biological Sciences, University of Nebraska, Lincoln, Nebraska, United States of America.
Owen NgalamikaDermatology and Venereology section, University Teaching Hospitals, University of Zambia School of Medicine, Lusaka, Zambia.ORCID 0000-0002-0648-4128
John R NgowiOcean Road Cancer Institute, Dar es Salaam, Tanzania.ORCID 0000-0002-3583-1758
Julius MwaiselageOcean Road Cancer Institute, Dar es Salaam, Tanzania.
Paul M LiebermanWistar Institute, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-3935-9921
John T WestNebraska Center for Virology and the Department of Biochemistry, University of Nebraska, Lincoln, Nebraska, United States of America.ORCID 0000-0003-4594-6855
Charles WoodNebraska Center for Virology and the School of Biological Sciences, University of Nebraska, Lincoln, Nebraska, United States of America.ORCID 0000-0002-4256-1530
University of Nebraska–Lincoln · USThe Wistar Institute · USMuhimbili University of Health and Allied Sciences · TZOcean Road Cancer Institute · TZUniversity Teaching Hospital · ZM

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
Regulation of KSHV LatencyR01CA117830 · NCI · WISTAR INSTITUTE · PI PAUL M. LIEBERMAN · 2006 to 2026
$6.4M
Seroprevalence of COVID-19 of cancer patients in TanzaniaU54CA190155 · NCI · UNIVERSITY OF NEBRASKA LINCOLN · PI SOLIMAN, AMR, WOOD, CHARLES · 2014 to 2022
$4.5M
Zambia AIDS Malignancies Diagnosis and Pathogenesis Program SupplementU54CA221204 · NCI · UNIVERSITY OF NEBRASKA LINCOLN · PI WOOD, CHARLES · 2017 to 2022
$3.8M
KSHV,HIV and the Kaposi's Sarcoma Tumor NicheR01CA228178 · NCI · UNIVERSITY OF NEBRASKA LINCOLN · PI WEST, JOHN T., WOOD, CHARLES · 2018 to 2024
$2.9M
AIDS Malignancies Training and Research International Program (AMTRIP)D43TW010354 · FIC · UNIVERSITY OF NEBRASKA LINCOLN · PI Chipepo Kankasa, Charles Wood · 2016 to 2026
$2.8M
Development of a Small Molecule Inhibitor for KSHV LANAR01CA186775 · NCI · WISTAR INSTITUTE · PI LIEBERMAN, PAUL M. · 2014 to 2018
$2.0M
Integrative Approach to Comprehensive Analysis of High Throughput Data on a Cancer Center LevelR50CA211199 · NCI · WISTAR INSTITUTE · PI Andrew V Kossenkov · 2016 to 2026
$1.6M
"Plasma and cellular immune biomarkers of Kaposi's sarcoma in HIV-1 suppressed patients"K43TW011418 · FIC · MUHIMBILI UNIVERSITY/ ALLIED HLTH SCIS · PI LIDENGE, SALUM JUMA · 2019 to 2023
$741k
FIC NIH HHS D43 TW010354FIC NIH HHS K43 TW011418NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA117830NCI NIH HHS R01 CA186775NCI NIH HHS R01 CA228178NCI NIH HHS R50 CA211199NCI NIH HHS U54 CA190155NCI NIH HHS U54 CA221204
6 · The paper itself

Abstract

In sub-Saharan Africa, endemic Kaposi's sarcoma (EnKS) is still prevalent despite high incidence of epidemic Kaposi's sarcoma (EpKS) resulting from the on-going HIV-1 epidemic. While KSHV is clearly the etiologic agent of KS, the mechanisms underlying KS development are not fully understood. For example, HIV-1 co-infection and concomitant immune dysfunction have been associated with EpKS development. However, the direct or indirect role(s) of HIV-1, and therefore of immune suppression, in EpKS remains unclear. How, or whether, EpKS is mechanistically distinct from EnKS is unknown. Thus, the absence of HIV-1 co-infection in EnKS provides a unique control for investigating and deciphering whether HIV-1 plays a direct or indirect role in the EpKS tumor microenvironment. We hypothesized that HIV-1 co-infection would induce transcriptome changes that differentiate EpKS from EnKS, thereby defining the direct intra-tumor role of HIV-1 in KS. Comparison of ART-treated and -naïve patients would further define the impact of ART on the KS transcriptome. We utilized RNA-seq followed by multiparameter bioinformatics analysis to compare transcriptomes from KS lesions to uninvolved control skin. We provide the first transcriptomic comparison of EpKS versus EnKS, ART-treated vs-naïve EpKS and male vs female EpKS to define the roles of HIV-1 co-infection, the impact of ART, and gender on KS gene expression profiles. Our findings suggest that ART-use and gender have minimal impact on transcriptome profiles of KS lesions. Gene expression profiles strongly correlated between EpKS and EnKS patients (Spearman r = 0.83, p<10-10). A subset of genes involved in tumorigenesis and inflammation/immune responses showed higher magnitude, but not unique dysregulation in EnKS compared to EpKS. While gender and ART had no detectable contribution, the trend toward higher magnitude of gene dysregulation in EnKS coupled with the absence of HIV-1 transcripts in EpKS may suggest an indirect or systemic effect of HIV-1 to promote KS tumorigenesis.

Indexed as

Herpesvirus 8, HumanHIV-1AdultCoinfectionFemaleGene Expression ProfilingHIV InfectionsHumansMaleMiddle AgedSarcoma, KaposiYoung Adult

Identifiers

PMID32706839
PMCPMC7406108
OpenAlexW3044161811

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.